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Abstract: 
Radiolabeled nanoparticles (NPs) are finding an increasing interest in a broad range of 
biomedical applications. They may be used to detect and characterize diseases, to deliver 
relevant therapeutics and to study the pharmacokinetic/pharmacodynamic parameters of 
nanomaterials. The use of radiotracer techniques in the research of novel nanoparticles offer 
many advantages but there are still some limitations. The binding of radionuclides to 
nanoparticles has to be irreversible in order to prevent their escape to other tissues or organs. 
Due to the half-life of radionuclides, the manufacturing process is time-limited and difficult, 
and there is also a risk of contamination. This chapter present the main selection criteria for 
radionuclides and applicable radiolabeling procedures used for the radiolabeling of various 
nanoparticles. Also, an overview of different types of NPs that have so far been labeled with 
radionuclides is presented. 
Key words: Nanoparticles; radiolabeling; nuclear imaging; radionuclide therapy; 
biodistribution  
  
6.1 Introduction 
Nuclear medicine is a branch of medicine that uses radiation to provide information about the 
functioning of a person's specific tissue/organs or to treat a disease. Radiolabeled 
nanoparticles (NPs) represent a new class of agents with a great potential for nuclear 
medicine applications. The key advantage of using radiolabeled NPs is that a very small 
amount can allow to obtain information of great importance [1]. They may be used to detect 
and characterize disease, to deliver relevant therapeutics and to monitor the therapeutic effect 
as well. Furthermore radiotracer-based imaging either using single-photon emission 
computed tomography (SPECT) or positron emission tomography (PET) is particularly suited 
in the study of pharmacokinetic/pharmacodynamic parameters of nanomaterials and 
determination of their optimal nanodimensional architecture for tissue/organ regeneration. 
Measuring radiation from radioactive tracers attached to nanoparticles has been demonstrated 
to be a highly sensitive and specific method that allows accurate quantification, without limits 
to tissue penetration in any organ. Nuclear imaging approaches are very suitable for detection 
since they offer a high detection sensitivity at high temporal and spatial resolutions requiring 
a radionuclide concentration of around 10
-10 
M at the site of interest. 
Nanoparticulate agents typically demonstrate pharmacokinetic behavior different 
from that of small molecules [2] and provide flexible platforms for integration of multiple 
functional entities, including targeting ligands, multiple types of contrast materials and/or 
therapeutics. In contrast to traditional compounds used for radiopharmaceutical preparation, 
nanomaterials have an immense available surface area per unit of volume and tunable optical, 
electronic, magnetic, and biological properties. Generally, they can be tailored to meet the 
needs of specific applications and engineered to have different physicochemical properties 
that affect in vivo biodistribution: sizes, shapes, chemical compositions, surface chemical 
characteristics, and hollow or solid structures [3]. Efficient diagnosis/radiotherapy is provided 
  
through passive targeting based on the enhanced permeability and retention (EPR) effect 
(Fig. 1) and/or active targeting through incorporating a targeting moiety on a nanoparticle. 
Non-targeted NPs can accumulate in tumors since the tumor vasculature is usually leaky and 
without lymphatic drainage. Active targeting is achieved by functionalizing the NPs surface 
with suitable vectors including peptides, antibodies and other biomolecules, which recognize 
characteristic epitopes at the surface of the diseased cells. 
 
Figure 1. Passive targeting: reconstructed PET/CT imaging in Balb/c mice with 
68
Ga-
DOTA–polyamido-amine dendrimer acquired 1 h post administration; (a) the kidneys and 
urinary bladder in normal mice; (b) tumor uptake localized in the tumor-bearing mouse. 
(Reproduced with the permission of the Elsevier) [4] 
 
Radiolabeled antibodies may effectively target even single cancer cells in circulation 
[5] or small cancer cell clusters [6], thereby enabling a more specific radiation dose delivery, 
preventing damage to healthy tissues.  
 
6.2 Radiolabeling of nanoparticles: selection of radionuclides and optimization of the 
radiolabeling procedure  
Several key issues need to be addressed for the selection and application of radionuclides for 
the radiolabeling of NPs. In contrast to NPs production, the radiolabeling process is time-
limited and difficult because of the contamination risk. The handling of radionuclides has to 
be carried out in specially designed radiochemical laboratories with controlled ventilation and 
air conditioning, shielded remote handling facilities, and special equipment intended for the 
measuring of the radioactivity of the selected radionuclide.  There are two main methods for 
the fabrication of radionuclides: using a nuclear reactor or using a particle accelerator. These 
  
methods are complementary in providing a wide variety of radionuclides for the application 
in medicine and research (Fig. 2.).  
 
Figure 2. Radionuclides for the radiolabeling of nanoparticles. 
 
The ability to access radionuclides without the use of onsite accelerators or reactors 
depends on the availability of generator-produced radionuclides in which the parent 
radionuclide is produced from a reactor or cyclotron. A generator is a device that is used to 
extract one radionuclide from another. Molybdenum-99 (
99
Mo)/technetium -99m (
99m
Tc) 
generator is especially popular and very convenient. The differences in the half-lives and 
chemical properties of 
99
Mo (half-life 66 h) and 
99m
Tc (half-life 6 h) are exploited to separate 
them in the generator. This procedure can be repeated many times providing a nearly 
continuous supply of radionuclides at a low cost. Germanium-68/gallium-68, strontium-
82/rubidium-82 and tungsten-188/rhenium-188 are newly developed generators. 
 The selection criteria for radionuclides must be based on the physical data about the 
radionuclide and biological variables governing their use. The considerations for physical 
characteristics include the physical half-life, type of emissions, energy of the radiation(s), 
daughter product (s), method of production, and radionuclide purity. The biochemical aspects 
include tissue targeting, the retention of radioactivity in the organ/tissue, in vivo stability, and 
toxicity.  
 Diagnostic radionuclides are generally short-lived radionuclides capable to provide 
the necessary information on biodistribution, dosimetry, and the limiting or the critical organ 
or the tissue. Radionuclides for SPECT imaging decay by the emission of high-energy 
photons (), while PET radionuclides decay by emission of positrons (+). The selection of 
appropriate therapeutic radionuclides that emit α- or β- particles depends upon the nature, the 
  
extent, and stage of disease. These types of particulate radiations allow very high ionisation 
per length of travel. Therefore, they are fully deposited within a small range of tissue (usually 
in mm). The longer range of beta particles can still permit uniform tumor irradiation despite a 
possible heterogeneity of distribution of radioactivity within the tumor. Therapeutic 
radionuclides which also decay with γ-radiation can be advantageous if the energy and 
intensity are within the diagnostic range, as it provides the ability to visualize distribution of 
the radiolabeled NPs [7]. 
 The physical half-life of radionuclide plays a crucial role for measurements in the 
desired time frame, and it has to be considered which radionuclide or half-life, respectively, 
are suitable for the investigated question and pharmacokinetic profile. For measurements 
within a short (initial) time frame after intravenous administration, short-lived PET 
radionuclides have been applied, e.g., fluorine-18 (half-life 109.7 min), gallium-68 (half-life 
67.7 min) or even nitrogen-13 (half-life 9.97 min) [8]. Oppositely, if the half-life is too short, 
most decay will occur before the radiolabeled NPs targeting has reached the maximum tissue 
accumulation.  
 The major requirements of the radiolabeling procedure are that the labeling process 
does not significantly alter the structure or properties of the NPs and that the stability of 
radiolabeled product is sufficient to allow further in vivo tracking. Once the radiolabeling 
method for the selected radionuclide and NPs type is optimized, the radioactive part may be 
used not only to track nanoparticles but also for radiodiagnosis or radiotherapy.
 
Figure 3. Radiolabeling of nanoparticles. 
 
Depending on the radionuclide and the composition and structure of NPs, two 
approaches may be applied for efficient radiolabeling (Fig. 3): direct radiolabeling, mostly 
  
via nucleophilic/electrophilic labeling and coordination chemistry, or indirect radiolabeling, 
via a chelator or a complexing agent, which requires additional synthetic steps. Furthermore, 
radionuclides are possible to attach to whole particles synthesized in advance (post-synthesis 
approach), or they can be entrapped in nanoparticles during the synthesis (pre-synthesis 
approach). 
 The convenience, efficiency, and gentleness of radiolabeling procedures are some of 
the requirements that have to be met by radiolabeling methods. The binding of radionuclides 
to a nanoparticle has to be irreversible in order to prevent them to escape to other tissues or 
organs. Careful in vitro experiments for measuring the stability of radiolabeled NPs (mostly 
in serum) are generally required prior to in vivo studies. The biodistribution patterns of 
radiolabeled nanoparticles do not seem to be crucially affected by the radiolabeling approach. 
In general, radiolabeled NPs are excreted into the urinary tract via the kidneys and they 
mostly accumulate in the reticuloendothelial tissues, liver and spleen, due to the substantial 
uptake by the macrophages that are present in these organs. If they agglomerate and the size 
is relatively large, in range of micrometers, the highest uptake after intravenous 
administration occurs in the lungs [9]. 
6.2.1 Radiolabeling with gamma-emitting radionuclides  
Technetium-99m (
99m
Tc), indium-111 (
111
In), gallium-67 (
67
Ga) and iodine-125 (
125
I), are the 
most commonly used gamma-emitting radionuclides for NPs radiolabeling. These 
radionuclides emit single photons detected by a gamma camera that can view organs from 
many different angles.  
6.2.1.1. Radiolabeling with 
99m
Tc 
Radiolabeling with
 99m
Tc (half-life 6 h) accounts for about 80% of all nuclear medicine 
procedures worldwide.
 
This can be attributed to its ideal physical properties, such as its half-
life that allow for prolonged in vivo imaging and γ-photon single-energy emission at 140 keV, 
  
which are beneficial for effective imaging. The chemical form of 
99m
Tc occurs as 
99m
Tc-
pertechnetate
 
(
99m
TcO4
−
). In a chemical reaction, it is necessary to reduce its oxidation state to 
a lower value. Stannous chloride (SnCl2) is the most often used reducing agent. The direct 
method of 
99m
Tc-labeling of NPs is based on the fact that the reduced 
99m
TcO4 reacts with 
random groups such as hydroxyl, carboxylic, amino groups, etc. present on the surface of the 
NPs. A direct labeling method was used to label hydroxyapatite nanoparticles  (HApNP) 
[10], as well as astaxanthin-loaded solid lipid nanoparticles. The direct nose-to-brain delivery 
of the 
99m
Tc-labeled lipid NPs was evident by gamma scintigraphy imaging, suggesting their 
potential use for various neurological diseases [11]. Tassano et al. developed another direct 
labeling procedure via a tricarbonyl precursor [
99m
Tc(H2O)3(CO)3]
+
 for radiolabeling 
dendrimers [12]. This method has been proven to be effective for labeling various ligands, 
such as ethylendiamine-N,N′-diacetate, which have significant tumor uptake exclusively by 
passive targeting [13]. NPs loaded with these compounds have higher probability for tumor 
uptake. 
 Radiometals, both diagnostic (
64
Cu, 
68
Ga, 
89
Zr) and therapeutic (
90
Y and 
177
Lu) are 
best attached to NPs via chelation. The indirect chelator-mediated 
99m
Tc-labeling of NPs has 
been applied to a variety of NPs structures [14]. Helbok et al. performed efficient 
radiolabeling of PEGylated cholesterol liposomes and micelles via an acyclic 
diethylenetriaminepentaacetic acid (DTPA) chelator [15]. Also, PEG-liposomes can be 
labeled relatively easily and stably with 
99m
Tc after liposome synthesis, using a procedure 
which includes the conjugation of 
99m
Tc to hexamethyl propyleneamine (HMPAO) [16] or 
hydrazino nicotinamide (HYNIC) [17] followed by their encapsulation into liposomes. The 
HYNIC-based method provides 
99m
Tc-labeled liposomes with a high labeling yield (>95%) 
and improved in vitro and in vivo characteristics compared to the liposomes labeled via 
99m
Tc-HMPAO.
 
Chitosan hydrogel NPs loaded with a vascular endothelial growth factor (a 
  
potent angiogenic factor) were efficiently labeled with 
99m
Tc via a DTPA chelator. The 
quantitative imaging with 
99m
Tc-chitosan nanoparticles has been demonstrated to be a 
valuable strategy that can be combined with an angiogenic therapy to customize the treatment 
of myocardial ischemia [18]. Mercapto-acetyl-triglycine (MAG3) has been applied to 
facilitate radiolabeling of morpholinos [19]. Meso-2,3-dimercaptosuccinic acid (DMSA) is 
also a suitable ligand that forms complex compounds with 
99m
Tc, 
186
/
188
Re,, 
166
Ho, 
177
Lu and 
90
Y. DMSA enables bidentate bindinding via two sulfur atoms on silver nanoclasters (Fig. 4.) 
and additional radiolabeling is possible via the binding of radiometals to DMSA [20].  
 
Figure 4. Bidentate-binding of meso-2,3-dimercaptosuccinic acid on silver nanoclusters. 
(Reproduced with the permission of the Elsevier) [20] 
 
In some chelating systems it is possible to apply a theranostic approach by 
substituting the diagnostic radionuclide with a therapeutic one, whereas the chelator and the 
nanodimensional structure remain. Due to the similar chemical properties of 
99m
Tc for 
188
Re, 
the labeling procedure is based on the similar complexation chemistries of two radionuclides 
with the same vector. 
Further studies on indirect NPs 
99m
Tc-labeling may include the investigation of novel 
ligands, such as diamino dioxime ligands that form a neutral and lipophilic complex with 
99m
Tc. The specified ligand and those that are chemically similar to it pass easily through the 
intact blood brain barrier. Accordingly, they have a high potential in cerebral perfusion 
imaging [21]. Iron oxide nanoparticles (IO-NPs) may be labeled with a variety of diagnostic 
and therapeutic radionuclides via direct and indirect, chelator-based radiolabeling techniques. 
The 
99m
Tc-labeled aminosilane-coated IO-NPs may be promising candidates for guided 
cancer diagnosis and magnetic hyperthermia therapy. Targeting is enabled via the 
  
conjugation with a new peptide-based Arg-Gly-Asp (RGD) derivate, which has a high 
affinity and selectivity for the ανβ3 integrin receptor presented in several tumors. The 
specific character of 
99m
Tc-NPs-RGD was confirmed in a receptor blocking study, in which 
the co-administration of an excess amount of the native peptide blocked an experimentally 
induced U87MG tumor (with an over-expression of the ανβ3 receptors). This resulted in a 
significantly reduced uptake of 
99m
Tc-NPs-RGD, indicating the specific character of the 
targeted IO-NPs (Fig.5.) [22].  
 
Figure 5. Active targeting: representative planar γ images of 99mTc-NPs-RGD (non-blocked 
(A) and blocked (B)) of a U87MG tumor bearing mouse at 1h p.i. (Reproduced with the 
permission of the Elsevier) [22] 
 
6.2.1.2. Radiolabeling with 
111
In 
Indium-111 (
111
In), is a readily available gamma-emitting radiometal, which is widely used in 
clinical practice for diagnosis [23]. Several methods for the radiolabeling of NPs are 
described in the literature, involve their conjugation with a chelate. The coupling of 
111
In to 
NPs can be achieved by chelating molecules like DTPA or DOTA, which are conjugated to 
the polymers as in the case of 
111
In-DTPA-PEG-b-PCL micelles. Polyethylene glycol (PEG) 
is an artificial but biocompatible hydrophilic polymer that has been widely applied for NPs 
coating. The radiotracer method has been used to prove that it is possible to use PEG 
derivatives as tumor imaging carriers. After 
111
In-labeling via DTPA, in vivo biodistribution 
studies demonstrated an increased tumor uptake and a prolonged circulation half-life with the 
increase of the molecular weight of PEG [24]. NPs that degrade and radionuclides that detach 
or are released from the NPs can cause artifacts. Dual radiolabeling using gamma emitters 
with different energy spectra incorporated into the core and coating may be used as a general 
  
methodology for a wide range of engineered NPs for the visualization of the degradation 
process of NPs in vivo. In order to label the core, 
111
In-doped iron oxide NPs were 
encapsulated inside poly(lactide-co-glycolide) nanoparticles (PLGA-NPs) during the 
preparation. The bovine serum albumin coating was labeled by electrophilic substitution 
using 
125
I. Imaging revealed different fates for the core and coating, with a fraction of the two 
radionuclides co-localizing in the liver and lungs for long periods of time after 
administration, suggesting that NPs are stable in these organs [25]. The conjugation of 
chelating agents to nanoparticles could affect their biodistribution. The attachment of such a 
chelate could alter the corona of the micelles and, consequently, their biodistribution and 
pharmacokinetics. Similarly to other radionuclides, 
111
In may also be entrapped in the 
micellar core during the formation of micelles without the need for any chemical 
modification [26].  
 Polymeric micelles (Lactosome) were labeled via 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) with 
111
In and 
90
Y for SPECT imaging and radiotherapy, 
respectively. Biodistribution studies revealed that 
111
In-DOTA-Lactosome was selectively 
accumulated in the tumor site of mice due to the EPR effect. The anti-tumor therapeutic 
effect of 
90
Y-DOTA-Lactosome was observed depending on the dose frequency and amount 
[27]. 
6.2.1.3. Radiolabeling with 
67
Ga 
Gallium-67 (
67
Ga) is a cyclotron-produced radiometal used for the imaging and localization 
of inflammatory lesions (infections). To get a better insight into the transport mechanism of 
peptide-conjugated NPs to tumors, bombesin (BBN) peptide-functionalized gold 
nanoparticles (AuNPs) were indirectly labeled with 
67
Ga and in vivo biological studies of 
67
Ga-labeled AuNPs in human prostate tumor-bearing mice were performed. In the case of 
67
Ga, the DTPA derivatives are unable to provide a stable coordination of 
67
Ga with AuNPs. 
  
Therefore, 
67
Ga-labeling was pursued via DOTA-containing AuNPs. For intravenous 
administration, the receptor-mediated pathway appears to be outweighed by the EPR effect 
while for the intraperitoneal administration, it has been concluded that the gastrin-releasing 
peptide receptor-mediated mechanism plays a role in pancreas uptake [28]. 
6.2.1.4. Radiolabeling with radioisotopes of iodine  
Isotopes of iodine have been extensively used in clinical nuclear medicine imaging and 
radiation therapy. Out of 37 known isotopes of iodine, four - 
123
I, 
124
I, 
125
I, and 
131
I - are 
suitable for SPECT or PET imaging. With a 60-day half-life, -emitter 125I is useful for the 
long-term tracking and imaging of radiolabeled NPs. 
131
I (half-life 8 d) is a strong gamma 
emitter, but due to its mode of beta decay, it is used for beta therapy, commonly in treating 
thyroid cancer. Dual-purpose theranostic radionuclides, e.g. 
131
I, or the pair 
124
I/
131
I can be 
used for imaging followed by therapy using the same radiolabeling procedure. 
 The traditional radiolabeling method with iodine radioisotopes is nucleophilic halogen 
exchange based on chloramine-T-oxidation (referred to as the Iodogen method) by direct 
radioiodination or by using prosthetic groups, such as tyrosine residues of proteins [29]. Tang 
et al. synthesized a SPECT/MRI/optical trimodality probe by labeling fluorescent silica-
coated IO-NPs with 
125
I using the Iodogen oxidation method. A radioactive probe was used to 
label mesenchymal stem cells (MSCs) and quantitatively track their migration and 
biodistribution in ischemic rats [30].  
 The radio-tracer technique has been demonstrated to be a relevant approach to the 
study the biodistribution of fullerenes (C60). Although watersoluble C60 derivatives 
(polyhydroxylated fullerene C60(OH)n) were successfully radiolabeled with different 
radiotracers, including 
67
Ga, 
99m
Tc, 
125
I or 
14
C, similar studies have not been performed with 
nano C60. The study of Nikolic et al. [31]
 
described for the first time the efficient 
125
I-labeling 
of the solvent exchange-produced C60 nanoparticles based on the intercalation of 
125
I into 
  
fullerene crystals during the colloid preparation. Fullerene molecular crystals are filled with 
THF molecules, but Na
125
I ion pairs are also entrapped, much more in the case when Na 
125
I 
was added during than after the C60 dissolution (Fig. 6).  
 
Figure 6. The proposed structure of radiolabeled C60 containing Na
125
I ion pair intercalated 
in its crystalline lattice. (Reproduced with the permission of the IOP Science) [31] 
 
The labeling of particles after the preparation usually requires some chemical 
modification. HApNPs were modified with aminopropyltriethoxysilane to introduce amino 
groups on the surface of hydroxyapatite for effective radioiodination [32]. Labeling without 
any modification achieved by adding the oxidizing agent chloramine T in situ during the 
formation of HAp resulted in the reproducible high labeling yield of 
125
I-labeled HAp [33]. 
6.2.2 Radiolabeling with PET radionuclides  
Fluorine-18 (
18
F, half-life 109.8 min), copper-64 (
64
Cu half-life 12.7h), iodine-124 (
124
I), 
gallium-68 (
68
Ga, half-life 68 min) and zirconium-89 (
89
Zr, half-life 78.4 h) are positron 
emitting radionuclides mostly used for PET functional imaging. Compared to SPECT 
imaging, PET imaging may offer increased accuracy, higher sensitivity, and better resolution 
[34]. PET is a more recent development in medicine and it uses radionuclides produced in a 
cyclotron. A cyclotron is a type of particle accelerator in which charged particles accelerate 
outwards from the centre along a spiral path. Limitations to the widespread use of PET arise 
from the high costs of cyclotrons needed to produce the short-lived radionuclides for PET 
scanning; the need for a specially adapted on-site chemical synthesis apparatus for 
radiolabeling; and a PET imaging facility in close proximity to the cyclotron due to the short 
half-life of most positron-emitting radionuclides. Furthermore, liposomes and some other 
NPs are the products of multiple steps which require a much longer process related to the 
half-lives of commonly used positron emitter nuclei. Thus, labeling methods in which 
  
components of liposome or preformulated drugs are substituted with short lived positron-
emitting radionuclides is impractical. 
 Urakami et al. [35] developed a rapid and efficient labeling method for lipid NPs via 
1-[
18
F] fluoro-3,6-dioxatetracosane without changing their physiological properties. Dynamic 
PET scanning showed that liposome-encapsulated hemoglobin (LEH) delivers oxygen even 
into the ischemic region from the periphery toward the core of ischemia. In recent years, the 
use of PET isotopes with a relatively long half-life (
64
Cu, 
89
Zr and 
68
Ga) has been increased. 
These metals can be coupled in a straightforward fashion using chelators, such as DTPA, 
DOTA, 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), 1,4,8,11-
tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (TETA), and derivatives of these 
macrocyclic chelating agents. Originally, DOTA was designed for lanthanides (e.g. Gd
3+
), 
but it can be used for a wide range of radiometals as well. Since DOTA has four carboxylic 
functions on the side-chains of the macrocycle bearing four nitrogens, the binding of 
64
Cu 
leads to deformed octahedral complexation of the Cu
2+
 ion, thereby leaving two of the acidic 
functions free. Accordingly, one is available for the coupling to NPs or polymers and the 
other allows further derivatization, or acts as an additional hydrophilic group. The review of 
Stockhofe at al. [36] presents a comprehensive study on various approaches and methods for 
the labeling of potential drug delivery systems using positron emitters. 
 
64
Cu has favourable decay characteristics, (+: 0.653 MeV, 17.4%; -: 0.578 MeV, 
39%) for both PET and radiotherapy and due to the half-life of 12.7 h it has been shown to be 
very effective for assessing the behaviour of nanomaterials in vivo for prolonged times. The 
functionalization of PMMA-core/PEG-shell nanoparticles with a DOTA ligand allowed for 
the chelation of 
64
Cu and enabled the investigation of the biodistribution of these materials in 
correlation to the molecular weight of the backbone and the PEG grafts [37]. The method for 
64
Cu-labeling via NOTA as the chelator was developed in the case of cRGD-functionalized 
  
and doxorubicin (DOX)-conjugated IONPs for potential application in drug delivery and 
PET/MRI dual-modality imaging [38]. Also, the application of an improved 
64
Cu labeling 
procedure via novel amine-activated chelator (amine-Bz-DOTA) conjugated to the surface of 
dextran sulfate coated IONPs, enabled to avoid cross-linking of IONPs (which caused NPs 
aggregation) and obtain a higher labeling yield [39]. Additional binding of tumor-specific 
antibodies to 
64
Cu-labeled doxorubicin loaded silica-based NPs provided an increased 
accumulation at the tumor site via an enhanced permeability, the retention effect and 
antibody-mediated binding to tumor [8].  
 The use of 
68
Ga (positron emission intensity 87%) is on the rise due to several 
identifiable properties of this radionuclide. These include a superior image quality to that 
provided by SPECT radionuclides and the potential for on-demand production via a generator 
(
68
Ge/
68
Ga-generator) [40]. Successful 
68
Ga-labeling requires a chelating agent and so far, 
DOTA and NOTA chelators have been used to radiolabel organic and inorganic nanodimensional 
systems with 
68
Ga cation. Polyamido-amine dendrimer (PAMAM) was conjugated 
successfully with bi-functional chelate N-hydroxysuccinimide ester of DOTA and the 
subsequent radiolabeling with 
68
Ga was achieved with a high radiolabeling yield and 
stability. However, DOTA-like macrocycles are not the best ligands for Ga
3+
 as the 
incorporation of ions inside the macrocyclic cavity leads to severe distortion of the 
coordination octahedra around the Ga
3+
 ions. NOTA-like ligands with a bis(phosphonate)-
containing side arm (as the bone targeting group) connected to a metal-binding cage through 
acetamide or methylphosphinate pendant arms, (NOTAM
BP
 and NO2AP
BP
) have been shown 
as highly potent chelators for small 
68
Ga
3+
 ions [41]. Synthetic apatite nanocrystals have 
demonstrated an excellent ability to bind two PET radionuclides, 
18
F and 
68
Ga, with a good in 
vitro stability. Na
18
F was used for the direct incorporation of the radionuclide into the crystal 
  
lattice, while the labeling by surface functionalization was accomplished by using 
68
Ga-
NO2AP
BP
.  
6.2.3 Radiolabeling with therapeutic β-emitting radionuclides  
Currently, radionuclide therapy remains an important treatment option. The ionizing radiation 
from radionuclides can kill cells or inhibit the growth in the periphery and the inaccessible 
centers of cancerous lesions. The sites of damage comprise all cellular levels, especially 
DNA in the nucleus of cells [42]. Internal radiotherapy relies on the implantation of 
radioactive seeds, such as radiolabeled micro- and nanoparticles delivering highly localized 
doses to a diseased area. Due to the inhomogeneous distribution of radiolabeled particles, 
especially within large tumors with a necrotic center, long-range -emitters with lower LETs 
and greater annihilation distances of several cells (typically 0.2-12 mm) provide a larger and 
tortuous radioactive dose volume. Yttrium-90 (
90
Y), lutetium-177 (
177
Lu) and rhenium-188 
(
188
Re) are proposed as suitable candidates for the internal radionuclide therapy, especially of 
primary and metastatic malignancies, while alpha- and Auger-emitters, due to their short 
range in tissues, would be more appropriate for the effective killing of circulating cells with a 
minimal irradiation of the blood [43]. No more than a few studies were conducted with α-
emitting radionuclides, such as 
225
Ac (half-life 10 d), which were mostly attached through 
chelation [44].  
6.2.3.1 Radiolabeling with 
90
Y  
90
Y is a high-energy -emitter with optimal nuclear physical characteristics (half-life 64.1 h, 
Emax=2.27 MeV) for radionuclide therapy. It can affect tumor cells up to a maximum depth of 
11 mm in the soft tissue. This is described by the cross-fire effect occurring due to the long 
path of -particles that crosses multiple individual cells decreasing the need for targeting 
each cancer cell with the radiopharmaceutical. Radiolabeled NPs, such as 
90
Y-silicate/citrate 
colloid and 
186
Re-sulfur colloid, have been used for radiosinevactomy with very encouraging 
  
results, especially in Europe [45]. The method is based on the local intra-articular injection of 
nanoparticulates/colloids labeled with suitable therapeutic radionuclides into a diseased joint, 
where they are phagocytized by the macrophages of the inflamed synovial membrane 
delivering a selective radiation dose to the synovium. 
90
Y-labeled colloid NPs, such as 
antimony trisulfide colloid (Sb2S3) [46] and tin fluoride colloid (SnF-c) [47] have a potential 
application in radiosinevactomy [48]. SnF-c particles were 
90
Y-labeled by the addition of 
90
YCl3 before the formation of primary particles (nucleation) and particle growth. These 
particles first aggregate and finally agglomerate due to the increased temperature, agitation, 
and aging (schematically represented in Fig. 7).The particle size of 
90
Y-SnF-c for different 
therapeutic applications is controllable by manipulating the conditions under which the 
colloids form. 
 
Figure 7. Formation of 
90
Y–SnF-c agglomerates from template particles and scintigraphic 
images recorded at 96h after intra-articular injection in Wistar rats. (Reproduced with the 
permission of the Wiley) [47] 
 
Among the different varieties of NPs proposed for use in radiosinevactomy, HAp hold 
considerable promise mainly due to its excellent properties [49]. Favorable properties of HAp 
(biocompatibility, the ease of synthesizing them within the desired particle size range, very 
high affinity for metal ions) have led to extensive studies on radiolabeled HApNPs with a 
wide variety of therapeutic radionuclides including 
90
Y [50] 
153
Sm [51], 
177
Lu [52], 
169
Er [53], 
166
Ho [54]. The direct labeling of HApNPs has been demonstrated to be a convenient and 
reproducible method for the facile preparation of 
90
Y-labeled HApNPs with a high 
radiolabeling yield (>98%) and radiochemical purity [55].  
  
 The direct labeling approach was also used for 
90
Y-labeling of both Fe3O4-naked and 
Fe3O4-PEG600diacid NPs [56]. The carboxylate-rich surface of Fe3O4-PEG600diacid NPs is 
suitable for labeling with positively charged 
90
Y
3+
. Therefore, the labeling resulted in a very 
high labeling yield (99%) and good in vitro and in vivo stability. Due to the significant uptake 
of 
90
Y-Fe3O4-PEG600 NPs in liver and their low uptake by other tissues, magnetite NPs 
labeled with beta-emitters could be suitable for use in the combined radiotherapy-
hyperthermia cancer treatment. Magnetic NPs coated with proteins, such as human serum 
albumin, were also effectively
 90
Y-labeled by the direct approach without any further surface 
chemical modification [57]. The indirect 
90
Y-labeling of NPs is possible via different ligands 
(2,3-dicarboxypropane-1,1-diphosphonic acid (DPD) (Fig. 8) [58], meso-dimercaptosuccinic 
acid (DMSA)) which are capable to form stable complexes with 
90
Y. 
 
Figure 8.  Indirect 
90
Y-labeling of NPs via DPD: the energy minimized structure of proposed 
complex 
90
Y-DPD. (Reproduced with the permission of the Elsevier) [58] 
 
6.2.3.2 Radiolabeling with 
177
Lu  
177
Lu (half-life 6.7 d ) is the ideal β− radionuclide for theranosis since it has a particulate 
emission (- or Auger electron) for effecting therapy and emits several accompanying gamma 
photons of 208 keV (11%) and 113 keV (6.4%), which are used for diagnostic evaluation and 
dosimetry [59]. The advantage of the long half-life of 
177
Lu has been utilized in mapping the 
pharmacokinetics of potential agents, in radiosinevactomy of knee joints and the therapy of 
hepatocellular carcinoma. Several studies were conducted with 
177
Lu-labeled gold NPs 
(AuNP) for imaging and therapy in tumor-bearing mice. AuNPs modified with PEG chains 
linked to DOTA made complex compounds with 
177
Lu. Gold nanoseeds injected 
intratumorally were highly effective for inhibiting the growth of breast cancer tumors in CD-
  
1 athymic mice and caused no normal organ toxicity [60]. Targeting with 
177
Lu-AuNPs 
conjugated to RGD (-Arg-Gly-Asp-) peptide showed a higher delivery into the tumor site 
than non-RGD and 
177
Lu-RGD controls, highlighting the potential therapeutic capacity of 
radiolabeled NPs for endoradiotherapy [61]. Based on the previous work, where 
68
Ga-labeled 
DOTA-conjugated bisphosphonates as PET imaging agents were investigated, a few DOTA -
based bisphosphonates were synthesized and labeled with 
177
Lu for potential application in 
treating metastatic bone tumors [62].
 
 
 
6.3 Radiolabeled NPs in nuclear medicine imaging and biodistribution studies 
Different types of NPs have so far been labeled with radionuclides - from inorganic, organic 
to the metal and hybrid ones. Due to their good mechanical properties, chemical resistance, 
biocompatibility and optical and electrical properties, diamond nanoparticles (ND) represent 
a special research challenge in radiolabeling technologies [63, 64]. Radiolabeled diamond 
nanoparticles may be suitable not only for bioimaging applications, due to their stability, but 
they may also have wider application. Their surface enables new possibilities for 
functionalization, as well as the uploading of suitable proteins and drugs. 
3
H-labeling of 
detonation nanodiamonds was performed by using tritium microwave (MW) plasma (Fig. 9) 
[65]. The analysis shows that 93% of the tritium atoms are strongly bound to the surface, 
while 7% are built into the ND core. 
 
Figure 9. Tritium labeled diamond nanoparticles (ND). (Reproduced with the permission of 
the Royal Society of Chemistry)[65] 
 
Exosomes are extracellular nano-sized vesicles that most cells produce. Macrophage-
derived exosome-mimetic nanovesicles (ENVs) were labeled with 
99m
Tc and their 
  
distribution was analyzed using the SPECT/CT technique in vivo. The results enabled to 
determine the highest accumulation of 
99m
Tc- ENVs in the liver [66].  
The biodistribution of PLGA nanoparticles with and without encapsulated ascorbic 
acid in healthy rats was examined after their direct labeling with 
99m
Tc, which binds outside, 
on the surface of nanoparticles [67]. The investigated nanospheres exhibit a prolonged blood 
circulation time accompanied with time-dependent reduction in the lungs, liver and spleen. 
This is a quick and convenient method to investigate the pharmacological behavior of a new 
nanoparticulate system for controlled and systemic drug delivery with a double effect [68, 
69]. In such a system, it is of utmost importance to study the release of drugs from 
bioresorbable polymers and, in the second stage, after the resorption of the polymer, to 
investigate the potential of non-bioresorbable calcium phosphate as a filler in a bone defect. 
The surface properties of PLGA/HAp core-shell nanoparticles loaded with clindamycin and 
their changes under the simulated physiological conditions during the degradation process 
could be also investigated using radiotracer method [70].  
 Radiolabeled nanomaterials based on graphene, including graphene, graphene oxide 
(GO), reduced graphene oxide (rGO), graphene quantumdots (GQDs), and their derivatives 
indicate their high potential as imaging agents in a variety of bioimaging applications, 
especially in the PET/SPECT [71]. 
111
In-MSN (mesoporous silica nanoparticle, MSN) proved 
to be suitable for the tracking of neural stem cells (NSCs) in glioblastoma therapies. 
Multimodal dynamic in vivo imaging of NSCs behavior in the brain is an important parameter 
in the design of a controlled, targeted and successful therapy. MSNs were labeled with 
111
In 
using DOTA-NHS-ester through amide formation. SPECT confirmed the ability of 
111
In-
MSN-NSCs to penetrate through the blood brain barrier (BBB) and their localization in 
tumor cells [72].  
  
Multimodality imaging by taking advantage of two or more imaging modalities can 
provide many structural, functional and molecular information of importance for the 
diagnosis and treatment [73]. It is possible to couple, e.g. MR-active NPs to a chelating 
system, thereby enabling in vivo tracking by multimodal imaging techniques (e.g. 
SPECT/MRI, PET/MRI). The synthesized core/shell nanoparticles of 
Co0.16Fe2.84O4@NaYF4(Yb, Er) and Fe3O4@NaYF4(Yb, Tm) were stabilized with 
bisphosphonate polyethylene glycol conjugates (BP-PEG) and radiolabeled with 
18
F or 
64
Cu 
and 
99m
Tc. The fabricated particles have shown the advanced features and the possibility of 
application in the trimodal imagining (MRI, PET/SPECT and fluorescent imaging). A high 
colloidal stability and a narrow size distribution (10 nm) allow for the potential use of these 
particles as visual guides during surgery [74]. 
64
Cu
2+ 
labeled natural biopolymer based 
multifunctional NPs were successfully used in cancer multimodal (PET/MRI/PAI) imaging 
techniques [75]. “Dragon fruit-like biocage” based on apoferritin (APF) was employed (Fig. 
10) to construct an efficient and excellent bio-stability nanoplatform (AMF) suitable for 
multimodal clinical application. 
 
Figure 10. Schematic illustration of AMF nanocage synthesis. (Reproduced with the 
permission of the Elsevier) [75] 
 
Radiolabeled ultrasmall (USNPs) nanoparticles with core sizes in the 1-3 nm range 
have shown specific features in biomedical applications. Due to the potential of USNPs for 
interactions with individual cells and the covalent attachment of small molecules, active 
molecular targeting can be effectively achieved [76]. 
68
Ga-labeled iron oxide has been 
successfully studied using PET/MR dual-modal imaging modality during specific 
accumulation in tumor cells [77]. 
65
Zn-labeled CdSe/CdS/ZnS-quantum dots (
65
Zn-Qdots) 
  
was used in order to achieve a full quantification of biodistribution and degradation during 
the in vivo test [78]. Depending on the attached or incorporated radioisotopes, USNPs 
systems have so far been mostly exploited in the SPECT and PET imaging modalities. 
The particles of poorly crystalline HAp (d50=72 nm) coated with chitosan (Ch), and 
the chitosan-poly-D,L-lactide-co-glycolide polymer blend (Ch-PLGA) have shown multi-
functional characteristics in bone tissue engineering [79]. 
125
I was used for the in situ 
radiolabeling of HAp, HAp/Ch and HAp/Ch-PLGA synthesized particles. Biodistribution 
studies have shown that after the intravenous administration to normal male Wistar rats, HAp 
particles have the highest liver accumulation 10 min after injection and rapid excretion from 
the body without residual radioactivity 24 hours after injection [33]. HAp/Ch particles have 
the highest accumulation in the liver 10 min after injection with considerable amount (almost 
50 %) retained 24 hours later. HAp/Ch-PLGA has the highest uptake in the lungs 10 minutes 
after injection and moderate retention in the same organ 24 hours later (Fig. 11). The results 
of the biodistribution of 
125
I-labeled particles based on HAp NPs indicate that they could be 
applied as organ-targeting carriers of various drugs in therapy. 
 
Figure 11. Biodistribution of a) 
125
I-HAp , b) 
125
I-HAp/Ch and c) 
125
I-HAp/Ch-PLGA. 
(Reproduced with the permission of the Elsevier) [33] 
 
Different approaches to the radiolabeling of super paramagnetic iron oxide 
nanoparticles (SPIONs) with 
14
C were tested in order to obtain a suitable system that could be 
used in the analysis of biodistribution. The concept of surface functionalization and formation 
of a multiple core system made it possible to obtain particles with a hydrodynamic radius 
smaller than 100 nm. NPs are functionalized with polycarboxylate or polyamine surface 
functional groups and 
14
C is incorporated directly into the carbon backbone of the organic 
  
molecules. This concept make is possible to obtain identical surface chemical functionality of 
labeled and non-labeled particles, enabling an accurate analysis prior to potential clinical 
application [80]. Nanoparticle carrier crown-ether-conjugated silica (SiNPs) is radiolabeled 
with 
22
Na with a loading efficacy of 98.1%±1.4%. Due to the relatively long half-life of 2.6 
years, this radionuclide has not had a wider application in biomedicine. However, for these 
reasons, 
22
Na may represent a practical choice in research. The one-month in vivo study on 
Female Balb/c mice (six weeks old) showed that 
22
Na-SiNPs were removed from the 
organism after two weeks, and completely after a month. The highest accumulation of 
particles was recorded in the liver 5 min. after intravenous administration [81]. Heat-induced 
metal ion binding reaction, which enables radiolabeling without modifying the surface 
structure, was used for the labeling of paramagnetic iron oxide nanoparticles. Feraheme (FH, 
solution composed of a non-stoichiometric Fe3O4 magnetite core approximately 5–10 nm in 
diameter stabilized with a carboxymethyl dextran coating; total size: 17-31 nm in diameter) 
NPs were labeled with 
89
Zr in a thermal reaction at 120°C in less than 60 minutes. The 
biodistribution of 
89
Zr-FHNPs 96h after the intravenous injection to mice indicated the uptake 
of 
89
Zr–FH in the lymphatic system [82]. 
In order to analyze and interpret the biodistribution of various components of multi-
component and more complex nano systems the concept of dual-radiolabeling of NPs was 
applied. Citrate-coated gold nanoparticles (monodisperse, 14 nm in diameter) were labeled 
with 
14
C and 
198
Au. By using liquid scintillation to determine 
14
C and gamma spectroscopy 
for 
198
Au different biodistribution profiles were determined for the Au core and the citrate 
surface coating over time. The obtained results of biodistribution show that over time the 
delamination and degradation of the citrate coating of NPs occur [83]. PLGA-coated iron 
oxide NPs were labeled with two gamma emitters 
111
In and 
125
I (Fig. 12) in the way that 
during the synthesis Au was labeled with 
111
In and PLGA with 
125
I. The energy-discriminant 
  
SPECT modality was used to analyze each radioisotope independently during the in vivo test 
with mice (BALB/cJRJ). The results showed that over time, the PLGA surface coating 
separated from the core since 
125
I was detected in the thyroid glands and urine, and 
111
In in 
the liver [25]. 
 
Figure 12. Schematic representation of dual-labeled [
125
I/
111
In] of PLGA-coated iron oxide 
NPs. (Source: J. Llop, et al., (2015)) [25] 
 
6.6 Radiolabeled NPs in therapy 
New research strategies in designing radiolabeled NPs are aimed at obtaining 
radiolabeled multifunctional nano objects that would accomplish specific and targeted 
therapy [84, 85]. Functional nanoparticles with active targeting (targeted nanoparticles, 
TNPs) could serve as carriers of radionuclides in the radio therapy of cancer with a high 
mortality of cancer cells while simultaneously sparing normal cells with minimal side effects 
[86]. HAp NPs radiolabeled with 
99m
Tc have shown a high stability during in vivo studies in 
mice. The results showed a higher affinity to bone tissues in contrast to the surrounding 
muscle tissue [87].  
In order to achieve a more specific targeting, TNPs are functionalized with various 
molecules. Anti-cancer therapeutic properties of the 
125
I labeled hybrid nano-sized cyclic 
Arg-Gly-Asp-conjugated GoldNPs (cRGD-GNPs) system were tested (including acute 
apoptosis two days post treatment and long-term influence up to 21 days). The results 
confirmed the effective targeting of tumor with 
125
I-cRGD-GNP and the suppression of its 
growth [88]. It has been demonstrated that the systems based on gold nanoparticles (GNPs) 
functionalized with an epidermal growth factor (EGF) as carriers of 
111
In are successful in the 
targeting and therapy of EGF receptor-positive cancers [89]. Targeted radiotherapy was also 
  
successfully achieved with conjugated surfaces of nano-systems on the basis of BSA (Bovine 
serum albumin) nanocapsules, silica, monoclonal antibodies (mAbs), etc [90-92]. 
Multifunctional nanoplatforms for the simultaneous use of radiotherapy and 
chemotherapy could enable significant progress in the field of nano-oncology. The designed 
lipid-polymer hybrid nanoplatform ChemoRad (Fig. 13), which contains PLGA and lecithin, 
was used as a suitable carrier for docetaxel, 
111
In and 
90
Y [93]. The results obtained with the 
prostate cancer model confirmed the realization of highly specific targeted delivery of the 
drug with highly effective radiotherapy at the same time.  
 
Figure 13. Schematic representation of the ChemoRad NPs. (Reproduced with the 
permission of the Elsevier) [94] 
 
6.7 Radiolabeled NPs in theranostics 
Multifunctional nanoparticulate systems with hybrid and improved properties are a result of 
creative research. Clear boundaries between objects for diagnostic imaging, therapy or 
biodistribution have almost disappeared. The term "theranostics" has unified the diagnostic 
and therapeutic potentials of the system into a single agent in order to achieve efficient, 
specific and individual therapy in various diseases [95]. 
Gadolinium-doped hydroxyapatite (HAp-Gd) nanorods could be used as theranostic 
nanoparticles to detect the early stages of osteosarcoma, or as carriers of radioisotopes in 
therapy. Gadolinium endows HAp with paramagnetic properties, while phosphorous and 
gadolinium in the HAp-Gd sample can be activated by neutron capture, in a nuclear reactor, 
producing 
32
P and 
159
Gd radioisotopes [96]. The multifunctional platform based on single-
walled carbon nanotubes (SWNTs) coated with a shell of polydopamine (PDA) was modified 
with polyethylene glycol (PEG). SWNT@PDA-PEG was labeled with 
131
I nucleotide, which 
  
potentially allows nuclear imaging and cancer therapy. An in vivo study in mice confirmed 
the accumulation of intravenously administered 
131
I-SWNT@PDA-PEG in the tumor tissues. 
The PDA coating allowed an easy labeling with 
131
I but also its delivery, due to which the 
system was able to perform radionuclide therapy as well [97]. 
A particular research challenge is focused on the preparation of radiolabeled 
nanoparticles with significant in vivo stability. A detailed analysis of the chelator-free radio-
labeling technique indicates the vital importance of deprotonated silanol groups during the 
labeling of mesoporous (MSN) (Fig. 14a) and nonporous (dSiO2) silica nanoparticles (Fig. 
14b) with 
89
Zr in order to obtain long stable systems. The in vivo study of the stability of 
these systems indicates that the detachment rate of 
89
Zr-MSN is about 20 times slower than 
that of 
89
Zr-dSiO2. The results obtained with PET modality indicated that the existence of 
mesochannels within MSN particles is responsible for the high stability of 
89
Zr-MSN system 
over a period of three weeks [98]. After the injection of 
89
Zr-MSN, their accumulation in the 
liver and spleen can be perceived, while the bone uptake is not present, which is not the case 
with 
89
Zr-dSiO2. 
 
Figure 14. 
89
Zr-labeled silica nanoparticles: a) mesoporous (MSN) and b) nonporous 
(dSiO2). (Adapted and reprinted with the permission of the American Chemical Society 
Publications) [98] 
 
A long circulation half-life of in vivo radiolabeled NPs leaves enough time for the 
EPR effect and the successful implementation of this type of particles in theragnostics. The 
64
Cu-labeled PEGylated reduced graphene oxide-iron oxide nanoparticles (
64
Cu-PEGylated 
RGO-IONPs) reaching about 68 nm in size were intravenously administered to mice which 
had an ischemic hind limb. On the basis of positron emission tomography (PET) and Doppler 
  
imaging it was determined that the accumulation of particles in the ischemic hind limb was 
the highest after three days and the lowest after 17 days [99]. 
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